Projects & Updates

RECIST – a case for RECIST in the presence of oligometastatic disease.

Oligoprogressive disease is the phenomenon in metastatic cancer where a small number of lesions progress, while the rest of the disease remains stable or continue to respond to systemic therapy. According to RECIST 1.1, these patients would be categorized as having progressive disease, and a patient would be taken off treatment. With the advent of immunotherapy, more and more protocols allow patients to stay on treatment beyond RECIST progression, as long as they are deriving clinical benefit. In some cases, the clinical benefit could be achieved by treating some progressing lesions with curative intent. Classical methods fail to provide guidance on how to continue follow-up in such situations.
The RECIST Working Group is currently evaluating the available evidence and aims to propose a framework for future research.

• Scott Laurie, Ottawa Hospital Cancer Center, CA
• Laure Fournier, Hôpital Européeen Georges-Pompidou, FR
• Saskia Litière, EORTC, BE

• Emiliano Calvo, Start Madrid, ES